Conversion of CellCept [mycophenolate mofetil] to Myfortic [mycophenolic acid]: A prospective study on the tolerability and safety of Myfortic in liver transplant recipients

Trial Profile

Conversion of CellCept [mycophenolate mofetil] to Myfortic [mycophenolic acid]: A prospective study on the tolerability and safety of Myfortic in liver transplant recipients

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Mycophenolate mofetil; Mycophenolic acid
  • Indications Liver transplant rejection
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Nov 2016 Status changed from recruiting to completed.
    • 13 Nov 2006 Status change
    • 25 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top